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DepressionThe long-acting, highly lipophilic, b2-adrenoceptor agonist clenbuterol may represent a suitable thera-
peutic agent for the treatment of neuroinflammation as it drives an anti-inflammatory response within
the CNS. However, clenbuterol is also known to increase the expression of IL-1b in the brain, a potent
neuromodulator that plays a role in provoking sickness related symptoms including anxiety and
depression-related behaviours. Here we demonstrate that, compared to the immunological stimulus
lipopolysaccharide (LPS, 250 lg/kg), clenbuterol (0.5 mg/kg) selectively up-regulates expression of the
central IL-1 system resulting in a mild stress-like response which is accompanied by a reduction in loco-
motor activity and food consumption in rats. We provide further evidence that clenbuterol-induced acti-
vation of the central IL-1 system occurs in a controlled and selective manner in tandem with its negative
regulators IL-1ra and IL-1RII. Furthermore, we demonstrate that peripheral b2-adrenoceptors mediate the
suppression of locomotor activity and food consumption induced by clenbuterol and that these effects
are not linked to the central induction of IL-1b. Moreover, despite increasing central IL-1b expression,
chronic administration of clenbuterol (0.03 mg/kg; twice daily for 21 days) fails to induce anxiety or
depressive-like behaviour in rats in contrast to reports of the ability of exogenously administered IL-1
to induce these symptoms in rodents. Overall, our findings suggest that clenbuterol or other selective
b2-adrenoceptor agonists could have the potential to combat neuroinflammatory or neurodegenerative
disorders without inducing unwanted symptoms of depression and anxiety.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Within the central nervous system (CNS), noradrenaline exerts
its anti-inflammatory and neurotrophic effects through actions at
glial b2-adrenoceptors (Day et al., 2014; Mori et al., 2002). Pharma-
cological stimulation of central b2-adrenoceptors holds promise as
a therapeutic target for the treatment of neuroinflammatory condi-
tions where deficiencies in the central noradrenergic system have
been implicated, such as Alzheimer’s disease, Multiple Sclerosis
and Parkinson’s disease (Feinstein et al., 2002; Hertz et al., 2004;
Marien et al., 2004). The long-acting brain penetrant b2-
adrenoceptor agonist clenbuterol represents a candidate therapeu-
tic agent for the treatment of neuroinflammation as it shows highaffinity for the b2-adrenoceptor (Liang and Mills, 2001), is highly
lipophilic in nature (Smith, 1998) and is resistant to rapid degrada-
tion and elimination from the body (Zalko et al., 1998). Clenbuterol
is already used in the treatment of respiratory disorders including
asthma and chronic obstructive pulmonary disease (Baronti et al.,
1980; Boner et al., 1988; Papiris et al., 1986). In addition, evidence
indicates that clenbuterol stimulates central glial b2-
adrenoceptors, induces production of neurotrophic factors, and
promotes anti-inflammatory and neuroprotective effects
(Culmsee et al., 1999a,b; Gleeson et al., 2010; Junker et al., 2002;
McNamee et al., 2010a,b,c; Semkova et al., 1996; Teng et al.,
2006; Zhu et al., 1999).
We have recently demonstrated that clenbuterol increases
expression of the inflammatory cytokine interleukin-1b (IL-1b) in
the CNS (McNamee et al., 2010a; Ryan et al., 2011). IL-1b has pre-
viously been implicated as a key mediator of neuroinflammation
(Allan et al., 2005; Griffin et al., 2006). While low levels of IL-1b
play a number of physiological roles in the CNS (Goshen et al.,
2007; Pinteaux et al., 2009; Spulber et al., 2009) excessive
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has been implicated in the neurodegenerative process (Allan et al.,
2005; Basu et al., 2004) and also in the pathogenesis of psychiatric
disorders such as depression and anxiety (Connor et al., 1998;
Goshen et al., 2008; Koo and Duman, 2008). IL-1b is a potent neu-
romodulator which can promote the expression of nitric oxide, the
prostaglandin synthase cyclooxygenase-II (COX-II) and other pro-
inflammatory cytokines such as tumour necrosis factor-a (TNF-a)
and interleukin-6 (IL-6) (Dinarello, 1996). This in turn can have
detrimental consequences for the CNS (Aschner, 1998;
Benveniste et al., 1995; Hofman et al., 1989; Patrizio, 2004;
Scheller and Rose-John, 2006; Tizard, 2008; Tracey, 2002). How-
ever, it must be noted that we have previously reported that the
clenbuterol-induced increase in IL-1b occurs in the absence of an
increase in other inflammatory cytokines such as TNF-a, IL-6 and
IFN-c (McNamee et al., 2010a; Ryan et al., 2011).
IL-1b signals by binding to the IL-1 type I receptor (IL-1RI) (Sims
et al., 1988). This receptor is present in the CNS (Lynch and Lynch,
2002; McNamee et al., 2010a; Parnet et al., 1994; Pinteaux et al.,
2002) but we have previously reported its expression to be
unchanged by clenbuterol administration (McNamee et al.,
2010a). The actions of IL-1b are regulated by IL-1 receptor antago-
nist (IL-1ra), which prevents IL-1b from acting on IL-1RI (Carter
et al., 1990), and by the IL-1 type II receptor (IL-1RII), a decoy
receptor that serves to sequester IL-1 (Colotta et al., 1994), both
of which are also expressed in the brain (Pinteaux et al., 2002,
2006). IL-1ra and IL-1RII are thought to prevent excessive or pro-
longed activation of the IL-1 system (Arend, 2002; Bessis et al.,
2000), thus it is noteworthy that increased expression of both
occurs in tandem with increased expression of IL-1b following
acute clenbuterol treatment in rat cortex (McNamee et al.,
2010a). Ultimately, this may serve to moderate the deleterious
effects of excessive IL-1b on brain function.
IL-1b, TNF-a, IL-6 and COX-II stand out as being the major play-
ers in the induction of sickness behaviour, the stereotypical beha-
vioural response of an animal to injury or infection (Hart, 1988)
and the actions of cytokines on the brain (Dantzer, 2001; Dantzer
et al., 2008; Hart, 1988). Thus, since clenbuterol is known to induce
the expression of IL-1b in the CNS (McNamee et al., 2010a; Ryan
et al., 2011), in study 1 we set out to confirm the hypothesis that,
as previously reported (McNamee et al., 2010a), clenbuterol
induces a selective increase in the IL-1 system in the brain, focus-
ing here on hippocampus and hypothalamus. Therefore, in this
study we investigated the expression of IL-b and other pro-
inflammatory mediators, namely TNF-a, IL-6 and COX-II following
acute administration of clenbuterol. In addition, we measured the
expression of the IL-1b receptors IL-1RI, IL-1RII, the antagonist IL-
1ra and the downstream signalling molecule inducible nitric oxide
synthase (iNOS). For comparative purposes systemic administra-
tion of the classical inflammagen lipopolysaccharide (LPS) was also
employed since LPS is known to potently induce the expression of
these pro-inflammatory mediators in the CNS several hours after
administration (Connor et al., 2008; Konsman et al., 2008;
O’Sullivan et al., 2009). In tandem to gain insight into the relative
activation of glial cells we examined the expression of the astro-
cyte and microglial activation markers glial fibrillary acid protein
(GFAP) and CD11b. As IL-1b is known to have profound effects on
behaviour in study 2 we investigated the impact of clenbuterol
on several physiological parameters, including body-weight, feed-
ing, locomotor activity, cardiac function and body-temperature,
since these have all been implicated in sickness behaviour
(Porter et al., 1998; Tizard, 2008; Zhou and Jones, 1993). Notably,
clenbuterol has previously been shown to induce behavioural
effects in rodents including suppression of locomotor activity and
feeding (Geyer and Frampton, 1988; Goldschmidt et al., 1984;
O’Donnell, 1993), however, the data are conflicting and themechanisms underlying these behavioural actions of clenbuterol
remain to be elucidated. We hypothesise that the induction of cen-
tral IL-1b by clenbuterol could mediate the suppressive beha-
vioural effects of clenbuterol. However, as b-adrenoceptors are
expressed on many cell types within both the peripheral and cen-
tral nervous system (Civantos Calzada and Aleixandre de Artinano,
2001; Hein, 2006; Hertz et al., 2004; Mori et al., 2002; Tanaka et al.,
2002; Xiang and Kobilka, 2003) in study 3 and 4 we investigated
the relative contribution of peripheral versus central b-
adrenoceptors in the behavioural actions of clenbuterol in order
to gain a better insight.
Neuroinflammatory and neurodegenerative disease states are
chronic in nature and require ongoing administration of therapeu-
tics. Therefore, in study 5 we sought to determine the lowest dose
of clenbuterol capable of impacting on immune processes in the
CNS which also has minimum peripheral effects that could be
administered over a prolonged period. Considering the evidence
that excessive production of IL-1b is implicated in the neurodegen-
erative process (Allan et al., 2005) and can precipitate symptoms of
depression and anxiety (Koo and Duman, 2008) in study 6 we
investigated the ability of chronic treatment with clenbuterol to
activate the central IL-1 system and to determine if clenbuterol
induces anxiety or depression-like behaviour in rats.2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats were obtained from Harlan Labora-
tories, UK (weight on arrival: 150–250 g). Rats were maintained
in an ambient temperature of 22 ± 2 C with lighting controlled
on a 12 h light-dark cycle (lights on: 08:00 h, lights off: 20:00 h).
Food and water were available ad libitum. The experimental proce-
dures employed were in compliance with the European Council
Directive (86/609/EEC). All animals were handled for at least four
days prior to experimentation to alleviate any stress caused by
experimental handling or injection.
2.2. Drugs
Clenbuterol and ICI 118,551 were obtained from Tocris Bio-
science, UK. LPS from Escherichia coli serotype 0111:B4, dexam-
ethasone, propranolol, nadolol and metoprolol were obtained
from Sigma-Aldrich, Ireland. All drugs were dissolved in saline
(0.9% (w/v) NaCl) and administered via the intraperitoneal (i.p.)
or subcutaneous (s.c.) route in an injection volume of 1 ml/kg, with
the exception of dexamethasone, which was dissolved in saline
containing Tween 20 (2% (v/v)). Saline was administered as a con-
trol. As both s.c. and i.p. are parenteral routes of injection which
have similar absorption profiles (Turner et al., 2011) we adopt
the s.c. route as a suitable alternative to the i.p. route when includ-
ing telemetrically determined parameters. Radiotelemetry devices
were implanted into the abdomen of the rat as previously
described (Harkin et al., 2002b). As the heart leads run from the
implanted device through two small holes in the abdominal wall
to the chest muscle to monitor heart rate (Harkin et al., 2002b) it
is not desirable to inject the animals i.p. for risk of disturbing these
leads.
2.3. Experimental design
2.3.1. Study 1 – Comparison of the neuroinflammatory response
elicited by both LPS & clenbuterol
Rats (n = 6–7) received an i.p. injection of either control, clen-
buterol (0.5 mg/kg) or LPS (250 lg/kg) and were euthanized 4 h
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vessels removed and a portion of hippocampus and hypothalamus
were dissected out and placed in RNAlater (Ambion, UK) to ensure
integrity of RNA for gene expression analysis. Samples were stored
at 80 C until mRNA expression analysis was performed.
2.3.2. Study 2 – Assessment of behavioural responses to LPS &
clenbuterol using telemetry
Rats (n = 6) implanted with radiotelemetry devices (see Sec-
tion 2.4.1) received an s.c. injection of either control, clenbuterol
(0.5 mg/kg) or LPS (250 lg/kg). Heart rate, body temperature and
locomotor activity of rats were monitored at 10 min intervals for
24 h. Changes in body-weight and food consumption were also
measured over the 24 h period.
2.3.3. Study 3: Investigation of the effect of pre-treatment with the
synthetic glucocorticoid dexamethasone, the peripherally acting b-
adrenoceptor antagonist nadolol or the centrally acting b-
adrenoceptor antagonist propranolol on clenbuterol-induced
behaviour and IL-1b expression in the brain
A) Rats were treated with either control containing Tween-20 or
dexamethasone (1 mg/kg; i.p.) 1 h prior to control or clenbuterol
(0.5 mg/kg; i.p.; n = 5). B) Rats were treated with either control or
nadolol (5 mg/kg; i.p.) 30 min prior to control or clenbuterol
(n = 6). C) Rats were treated with either control or propranolol
(10 mg/kg; i.p.) 30 min prior to control or clenbuterol (n = 5). Loco-
motor activity was measured 2 h post-treatment for 15 min. Fol-
lowing assessment of locomotor activity rats were returned to
their home cage and euthanized 4 h post-clenbuterol treatment.
The brain was dissected and tissue stored as detailed in
Section 2.3.1.
Separate groups of rats were housed individually and treated as
above. Food consumption was measured 24 h post-treatment. (A:
n = 5; B: n = 5–6; C: n = 5).
A dose of 1 mg/kg dexamethasone was chosen here as we have
previously demonstrated that this dose inhibits clenbuterol-
induced central IL-1b expression without altering its ability to
induce the anti-inflammatory mediators IL-1ra and IL-1RII (Ryan
et al., 2011). Rats were pre-treated with dexamethasone to ascer-
tain the impact of blocking clenbuterol-induced IL-1b expression
on locomotor activity and food consumption without affecting its
anti-inflammatory actions. A dose of 5 mg/kg nadolol was chosen
as this has previously been shown to block atropine-induced
tachycardia in rats (Hicks et al., 1998). A dose of 10 mg/kg propra-
nolol was used as this was previously shown by our group to block
the induction of central IL-1b (McNamee et al., 2010b).
2.3.4. Study 4: Effect of pre-treatment with the selective b1-
adrenoceptor antagonist metoprolol and the selective b2-adrenoceptor
antagonist ICI 118,551 on clenbuterol-induced behavioural changes
and IL-1b expression in the brain
Rats were treated with either control, ICI 118,551 (10 mg/kg; i.
p.) or metoprolol (10 mg/kg; i.p.) 30 min prior to control or clen-
buterol (0.5 mg/kg; i.p.) as previously described (Ryan et al.,
2013) and locomotor activity was measured 2 h post-treatment
for 15 min. Rats were then returned to their home cage and euth-
anized 4 h post-clenbuterol treatment. The brain was dissected and
tissue stored as detailed in Section 2.3.1 (n = 5–6).
A separate group of rats (n = 6) implanted with radiotelemetry
devices (see Section 2.4.1) was treated as above and heart rate
was subsequently monitored at 10 min intervals for 24 h.
The dose of ICI 118,551 used for the purposes of this study was
previously shown to significantly reduce clenbuterol-induced
apoptosis in the heart (Burniston et al., 2005) while the dose of
metoprolol was double the dose used previously by Zhang et al.
(2010) to attenuate the clenbuterol-induced increase in heart rate.2.3.5. Study 5: Dose related effects of clenbuterol
Clenbuterol (0.5 mg/kg) has profound peripheral effects includ-
ing elevated heart rate, reductions in core temperature and
reduced locomotor activity. Thus, we subsequently carried out
dose response experiments over a lower range of doses to deter-
mine the lowest dose at which clenbuterol can elicit an anti-
inflammatory response in rat CNS with minimal peripheral effects
which would be more suited for repeated treatment. In the first
instance rats were treated with either vehicle or clenbuterol over
a range of doses (0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg) and subse-
quently (0.003 mg/kg, 0.01 mg/kg and 0.03 mg/kg; i.p.) and loco-
motor activity was measured 2 h post-treatment for 15 min. Rats
were returned to their home cage and euthanized 4 h post-
clenbuterol treatment for determination of the expression of IL-1
signalling and glial markers as detailed in Section 2.3.1. Separate
groups of rats were housed individually and treated as above and
food consumption and body weight gain were measured over
24 h following clenbuterol administration. Data from both dose
response experiments were combined (n = 4–14).
2.3.6. Study 6: Effect of chronic low-dose clenbuterol on anxiety or
depression-related behaviour (anhedonia) and IL-1b expression in the
brain
Rats (n = 7–8) were treated with either control or low-dose
clenbuterol (0.03 mg/kg; i.p; twice per day (b.i.d)) at 8 am and
8 pm for 21 days (Fig. 1). This dose of 0.03 mg/kg was selected
based on results from study 5 in which it was the lowest dose
shown to impact on the IL-1 system and behaviour in addition to
being a more therapeutically relevant dose in humans (Daubert
et al., 2007). To test for anhedonia, a two-bottle saccharin prefer-
ence test was carried out for the duration of the study (see Sec-
tion 2.4.3) whereby the rats had free access to both water and
saccharin (0.01%). Rats were tested in the elevated plus maze
(see Section 2.4.4) on day 9 and in the open field (see Section 2.4.5)
on day 14 to assess anxiety-related behaviours. Rats were eutha-
nized on day 21, 4 h after the final injection. The brain was dis-
sected and tissue stored as described in Section 2.3.1.
2.4. Behavioural measures
2.4.1. Telemetry procedure
Battery-free radiotelemetry devices (PDT 4000HR E-Mitters,
Mini Mitter, OR, USA) were implanted into the peritoneal cavity
as previously described (Harkin et al., 2002b). Implantation of such
devices allows for the acquisition of data for heart rate, core body-
temperature and locomotor activity continuously reducing stress
associated with exposure of the animal to human contact. Heart
rate, body temperature and locomotor activity of rats were moni-
tored at 10 min intervals for 24 h using PDT 4000HR E-mitters
and the Windows PC-based acquisition system VitalViewTM (Mini-
Mitter, USA).
2.4.2. Measurement of locomotor activity
For the studies outlined in Sections 2.3.3–2.3.5 above, rats were
removed from their home cage 2 h post-clenbuterol treatment and
placed individually into activity monitor cages
(32 cm  20 cm  18 cm; length width  height) which were
connected to the AM1051 data logger (Benwick Electronics) and
active time was logged. Each activity monitor cage is equipped
with 2 sets of horizontal infrared beams, positioned at 3 cm and
15 cm above the base of the cage. Both sets of beams consist of a
12 beam by 7 beam matrix, forming a grid of 66  2.54 cm2 cells
within the cage. An animal was considered inactive if no beam
has been broken for 5 s. Locomotor activity measures were
recorded for 15 min, following which time the animals were
returned to their home cage.
Fig. 1. Chronic clenbuterol administration. Rats were habituated to saccharin exposure for four days prior to the start of the study. Rats were treated with either control or
low-dose clenbuterol (0.03 mg/kg; i.p; b.i.d) for 21 days. To assess anhedonia a two-bottle saccharin preference test was carried out for the duration of the study. Rats were
tested in the elevated plus maze on day 9 and in the open field on day 14 to assess anxiety-like behaviour. Rats were euthanized on day 21, 4 h after the final injection.
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The saccharin preference test, used as a test for anhedonia, was
carried out as previously described (Harkin et al., 2002a). Briefly,
animals were exposed to a saccharin solution (0.01%) or tap water
in standard drinking bottles in their home cage. The position of the
bottles was varied and counter balanced across the left or right side
of the feeding compartment. Bottles were weighed daily for 4 days
before the commencement of the study. This was carried out to
ensure that animals were subdivided into groups with comparable
baseline preference. Bottles were subsequently weighed every day
post-treatment. Fluid consumption was calculated by measuring
the daily difference in bottle weight. Preference scores were calcu-
lated by dividing the amount of saccharin consumed by the total
amount of fluid consumed (water + saccharin) over the 24 h expo-
sure period. There were 8 rats per treatment group in this study
and rats were housed 2 per cage. Cage-mates were in the same
treatment group. For saccharin preference measurements the total
drinking volumes for each cage of 2 animals was recorded, thus
there are 4 pairs per treatment group i.e. n = 4.
2.4.4. Elevated plus maze testing
The elevated plus maze was located in a windowless room
under dim light conditions. A video camera mounted at ceiling
height directly above the open field arena recorded activity during
the experimental period. Extra-maze cues (furniture, light source
and position of experimenter) were kept constant throughout the
study. This test is based on the natural aversion of rodents for open
spaces and uses an elevated plus-maze (38.5 cm from the floor)
with two open arms and two closed arms (30  5  15 cm). Ani-
mals were placed individually in the centre of the maze (junction
between open and closed arms) and behavioural performance
was scored over a period of 5 min. Light intensity was equal in
all arms of the maze. The maze was cleaned thoroughly with warm
water between trials.
2.4.5. Open field testing
The open field arena was located in a windowless room under
dim light conditions. A video camera mounted at ceiling height
directly above the open field arena recorded activity during the
experimental period. Extra-maze cues (furniture, light source and
position of experimenter) were kept constant throughout the
study. The open field consisted of a circular arena (120 cm diame-
ter) enclosed by walls (50 cm height). Two zones were defined in
the arena: a ‘‘safe” (peripheral) zone and an ‘‘unsafe” (central)
zone. At the start of the task the animal was placed in the centre
of the arena and left to explore for a period of 5 min. The followingparameters were determined using specialised computer software
from EthoVision (Noldus, The Netherlands): (1) time spent in the
inner and outer zone; (2) distance travelled in the inner and outer
zone; (3) number of entries into the inner zone. The open field
arena was thoroughly cleaned between each test.
2.5. Measurement of hypothalamic and hippocampal mRNA expression
using qRT-PCR
A Nucleospin RNA II Total RNA isolation kit (Machery-Nagel
GmbH & Co.) was used to extract RNA from tissue samples as per
the manufacturer’s protocol and as previously described (Ryan
et al., 2011). The concentration and purity of the RNA samples
was determined using a Nanodrop (Thermo Fisher Scientific). A
high-capacity cDNA archive kit (Applied Biosystems, UK) was used
to reverse transcribe RNA samples according to the manufacturer’s
protocol. Multi-target (Multiplex) qRT-PCR was carried out using
TaqMan gene expression assays containing specific target primers
and FAM-labelled MGB target probes (Applied Biosystems, UK) and
Taqman Universal PCR Master Mix on an ABI Prism 7300 instru-
ment (Applied Biosystems) as previously described (Boyle and
Connor, 2007). b-actin was used as an endogenous control to nor-
malize gene expression data. Relative gene expression was calcu-
lated using the DDCT method (Livak and Schmittgen, 2001) with
Applied Biosystems RQ software (Applied Biosystems, UK). Assay
IDs are detailed in Supplementary Table 1.
2.6. Statistical analysis of data
Data are expressed as mean ± standard error of the mean (SEM).
Statistical comparisons were performed using either a Student’s t-
test or a one- or two-way analysis of variance (ANOVA) followed by
a Student Newman-Keuls post-hoc test where appropriate. Saccha-
rin preference data were analysed using a two-way ANOVA with
repeated measures. A p-value <0.05 was deemed statistically
significant.3. Results
3.1. LPS induces a classical neuroinflammatory response while
clenbuterol selectively induces the expression of IL-1 system in rat
hippocampus and hypothalamus
One-way ANOVA revealed that there was an effect of treatment
on IL-1b mRNA expression (Fig. 2a) in hypothalamus
Fig. 2. Clenbuterol selectively induces IL-1b mRNA expression in rat hypothalamus and hippocampus while LPS induces IL-1b, TNF-a, IL-6 and COX-II mRNA expression
Clenbuterol (0.5 mg/kg), LPS (250 lg/kg) or control were administered i.p. and rats were sacrificed 4 h post-injection. a) Both LPS and clenbuterol increased the mRNA
expression of IL-1b in hypothalamus and hippocampus. b) LPS increased the mRNA expression of TNF-a in hypothalamus and hippocampus while clenbuterol failed to induce
TNF-a expression in either brain region. c) LPS increased the mRNA expression of IL-6 in hypothalamus and hippocampus while clenbuterol failed to induce IL-6 expression in
either brain region. d) LPS increased the mRNA expression of COX-II in hypothalamus and hippocampus while clenbuterol failed to induce COX-II expression in either brain
region. Data are expressed as mean fold-change with standard error of the mean (n = 6–7). ⁄p < 0.05, ⁄⁄p < 0.01 versus control, ++p < 0.01 versus LPS group (Newman-Keuls
post-hoc test).
118 K.M. Ryan et al. / Brain, Behavior, and Immunity 56 (2016) 114–129[F(2,17) = 12.79, p < 0.0004] and hippocampus [F(2,14) = 26.53,
p < 0.0001], TNF-a expression (Fig. 2b) in hypothalamus[F(2,17) = 11.54, p < 0.0007] and hippocampus [F(2,13) = 173.40,
p < 0.0001], IL-6 expression (Fig. 2c) in hypothalamus
Table 1
Comparison of clenbuterol- and LPS-induced mRNA changes in hypothalamus and
hippocampus. ⁄p < 0.05; ⁄⁄p < 0.01 versus Control.
Control Clenbuterol LPS
Hypothalamus
IL-1RI 1 ± 0.12 1.33 ± 0.06 1.60 ± 0.26⁄
IL-1RII 1 ± 0.09 244.53 ± 16.95⁄⁄ 30.73 ± 11.70⁄⁄
IL-1ra 1 ± 0.25 2.18 ± 0.11⁄ 2.10 ± 0.47⁄
iNOS 1 ± 0.17 14.06 ± 3.07 106.96 ± 27.21⁄⁄
CD11b 1 ± 0.15 1.09 ± 0.13 1.52 ± 0.24
GFAP 1 ± 0.47 8.63 ± 3.39⁄ 2.21 ± 1.34
Hippocampus
IL-1RI 1 ± 0.08 3.16 ± 0.92⁄ 2.50 ± 0.77
IL-1RII 1 ± 0.32 336.38 ± 42.25⁄⁄ 168.43 ± 53.56
IL-1ra 1 ± 0.14 9.13 ± 2.75⁄⁄ 4.70 ± 0.26
iNOS 1 ± 0.14 10.89 ± 1.58 77.69 ± 17⁄⁄
CD11b 1 ± 0.12 1.46 ± 0.05⁄ 1.59 ± 0.27⁄
GFAP 1 ± 0.06 1.59 ± 0.10⁄⁄ 0.91 ± 0.03
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p < 0.0068] and COX-II expression (Fig. 2d) in hypothalamus
[F(2,17) = 33.72, p < 0.0001] but not hippocampus [F(2,13) = 1.25,
p = 0.32] 4 h post-injection. Systemically administered LPS
increased IL-1b expression (Fig. 2a) in hypothalamus (p < 0.05)
but not hippocampus, TNF-a (Fig. 2b) in hypothalamus (p < 0.01)
and hippocampus (p < 0.01), IL-6 (Fig. 2c) in hypothalamus
(p < 0.01) and hippocampus (p < 0.01) and COX-II (Fig. 2d) in
hypothalamus (p < 0.01) but not hippocampus 4 h post-injection.
In order to examine the induction of IL-1b expression by LPS, the
control and LPS groups were isolated and analysed using a Stu-
dent’s t-test. This was necessary since the robust clenbuterol-
induced increase in IL-1b expression precluded the detection of
differences between the control and LPS groups. In contrast, sys-
temically administered clenbuterol selectively induced the expres-
sion of IL-1b in both hypothalamus (p < 0.01) and hippocampus
(p < 0.01) (Fig. 2a). One-way ANOVA revealed an effect of treat-
ment on IL-1RI in hypothalamus [F(2,17) = 3.75, p = 0.04] and hip-
pocampus [F(2,13) = 3.89, p = 0.05], IL-1RII in hypothalamus
[F(2,17) = 127.81, p < 0.0001] and hippocampus [F(2,13) = 30.62,
p < 0.0001], IL-1ra in hypothalamus [F(2,17) = 5.20, p = 0.02] and
hippocampus [F(2,14) = 21.55, p < 0.0001], iNOS in the hypothala-
mus [F(2,17) = 15.84, p = 0.0001] and hippocampus [F(2,14) = 32.07,
p < 0.0001]. LPS increased the expression of IL-1RI (p < 0.05), IL-
1RII (p < 0.01), IL-1ra (p < 0.05) in the hypothalamus and iNOS in
the hypothalamus (p < 0.01) and hippocampus (p < 0.01) (Table 1).
Clenbuterol had a more profound effect than LPS increasing the
expression of IL-1RII in the hypothalamus (p < 0.01) and hip-
pocampus (p < 0.01), IL-1ra in the hypothalamus (p < 0.05) and
hippocampus (p < 0.01) and also on IL-1RI (p < 0.05) in the hip-
pocampus but not hypothalamus. Clenbuterol had no effect on
iNOS in either brain region. One-way ANOVA also revealed an
effect of treatment on GFAP in hypothalamus [F(2,17) = 3.61,
p = 0.05] and hippocampus [F(2,14) = 21.55, p < 0.0001] and CD11b
in hippocampus [F(2,13) = 4.73, p = 0.03] but not in hypothalamus
[F(2,17) = 2.51, p = 0.11]. Post-hoc analyses revealed an increase in
the expression of CD11b in the hippocampus (p < 0.05) following
LPS and clenbuterol. GFAP was increased in the hypothalamus
(p < 0.05) and hippocampus (p < 0.01) following clenbuterol but
was not affected by LPS in either brain region.
3.2. LPS induces sickness behaviour while clenbuterol induces a stress-
related response in rats
Locomotor Activity: LPS reduced the locomotor activity of rats, an
effect which persisted for approximately 12 h post-injection
(Fig. 3a). When locomotor activity data were pooled for the 12 h
lights-out period, one-way ANOVA revealed an effect of treatment
[F(2,72) = 20.56, p < 0.0001]. In this regard, LPS reduced locomotor
activity compared to controls (p < 0.01) and clenbuterol reduced
locomotor activity (p < 0.01) compared to controls, an effect which
persisted for approximately 12 h. When locomotor activity data
were pooled for the 12 h lights-out period one-wayANOVA revealed
no effect of treatment [F(2,63) = 1.41, p = 0.25]. Temperature: LPS
induced a febrile response in ratswhich persisted for approximately
10 h (Fig. 3b). When temperature data were pooled for the 12 h
lights-out period, one-way ANOVA revealed an effect of treatment
[F(2,72) = 107.03, p < 0.0001]. LPS significantly increased body-
temperature compared to controls (p < 0.01). In contrast, clen-
buterol reduced body-temperature of rats, an effect which persisted
for approximately 11 h.When temperature datawere pooled for the
12 h lights-on period, one-way ANOVA revealed an effect of treat-
ment [F(2,63)=47, p < 0.0001] clenbuterol decreased body-
temperature (p < 0.01) compared to controls. Heart rate: LPS
increased the heart rate of rats, an effectwhich persisted for approx-
imately 24 h (Fig. 3c). When the heart rate data were pooled for the12 h lights-out period, one-way ANOVA revealed an effect of treat-
ment [F(2,72) = 100.61, p < 0.0001]. LPS significantly increased heart
rate (p < 0.01) compared to controls. Similarly, clenbuterol also
increased the heart rate of rats (p < 0.01), an effect which again per-
sisted for approximately 24 h, however this was found to be of a
much greater magnitude than that observed with LPS. When heart
rate data were pooled for the 12 h lights-out period, one-way
ANOVA revealed an effect of treatment [F(2,72) = 100.61,
p < 0.0001]. Clenbuterol significantly increased heart rate compared
to controls (p < 0.01) and also compared to the LPS group (p < 0.01).
When the heart rate data were pooled for the 12 h lights-on period,
one-way ANOVA revealed an effect of treatment [F(2,63) = 492.12,
p < 0.0001]. Clenbuterol again increasedheart rate compared to con-
trols (p < 0.01) and also compared to the LPS group (p < 0.01). Food
consumption&body-weight: One-wayANOVAalso revealed an effect
of treatmenton food consumption [F(2,15) = 51.36, P < 0.0001]. Treat-
ment with LPS and clenbuterol both reduced food consumption
(Fig. 3d; p < 0.01) compared to controls over a 24 h period. One-
way ANOVA also revealed an effect of treatment on body-weight
gain [F(2,15)=7.58, p = 0.005] (Fig. 3e). However, while clenbuterol
reduced food consumption of rats to a comparable level as that
shownwith LPS it did not alter the body-weight gain of rats (Fig. 3e).3.3. The centrally acting b-adrenoceptor antagonist propranolol blocks
clenbuterol-induced stress responses and the increase in IL-1b
expression in the hypothalamus
Two-way ANOVA revealed an effect of clenbuterol on locomotor
activity [F(1,19) = 427.76, p < 0.0001] but no effect of dexametha-
sone on locomotor activity [F(1,19) = 0.002, p = 0.97] (Fig. 4a).
Two-way ANOVA revealed a dexamethasone x clenbuterol interac-
tion for food intake [F(1,16) = 11.73, p = 0.004] but post-hoc analyses
showed that dexamethasone failed to reverse the clenbuterol-
induced reduction in food intake (Fig. 4b). Two-way ANOVA
revealed a dexamethasone x clenbuterol interaction for IL-1b
[F(1,16) = 31.15, p < 0.0001]. Clenbuterol induced an increase
(p < 0.01) in hypothalamic IL-1b expression which was completely
blocked by pre-treatment with the synthetic glucocorticoid dex-
amethasone (Fig. 4c; p < 0.01). Two-way ANOVA revealed a nadolol
x clenbuterol interaction for locomotor activity [F(1,23) = 26.13,
p < 0.0001] and food intake [F(1,16) = 57.34, p < 0.0001]. Pre-
treatment with the peripherally acting b-adrenoceptor antagonist
nadolol inhibited the clenbuterol-induced suppression of locomo-
tor activity (Fig. 4d) and food consumption (Fig. 4e). Two-way
ANOVA revealed a nadolol x clenbuterol interaction for IL-1b
[F(1,23) = 14.85, p = 0.001] but post hoc analysis showed that nadolol
failed to attenuate the clenbuterol-induced increase in IL-1b
Fig. 3. LPS induces sickness behaviour while clenbuterol induces a stress-related response in rats. Clenbuterol (0.5 mg/kg), LPS (250 lg/kg) or control were administered s.c.
to rats and locomotor activity, body-temperature and heart rate were monitored over a 24 h period. a) Both clenbuterol and LPS reduced locomotor activity of rats. When data
were pooled for the lights out period both clenbuterol and LPS were found to reduce locomotor activity. b) LPS increases body-temperature while clenbuterol decreases body-
temperature of rats. When data were pooled for the lights out period LPS was found to increase body-temperature while clenbuterol was found to reduce body-temperature
of rats. c) Both clenbuterol and LPS increased heart rate of rats. When data were pooled for the lights out period both clenbuterol and LPS were found to increase heart rate. d)
Clenbuterol and LPS both reduced food intake of rats. e) LPS but not clenbuterol reduced body-weight of rats. Data expressed as means with standard error of the mean (n = 6).
⁄⁄p < 0.01, ⁄p < 0.05 versus control, ++p < 0.01 versus LPS group (Newman-Keuls post-hoc test).
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hypothalamic IL-1b (Fig. 4f; p < 0.01). Two-way ANOVA revealed
a propranolol x clenbuterol interaction for locomotor activity[F(1,23) = 47.38, p < 0.0001] and food intake [F(1,16) = 10.80,
p = 0.005]. Pre-treatment with the centrally acting b-
adrenoceptor antagonist propranolol inhibited the clenbuterol-
Fig. 4. The centrally acting b-adrenoceptor antagonist propranolol blocks clenbuterol-induced stress responses and the increase in IL-1b expression in the hypothalamus.
Rats were pre-treated with dexamethasone (1 mg/kg) 1 h prior to clenbuterol (0.5 mg/kg) treatment or nadolol (5 mg/kg) or propranolol (10 mg/kg) 30 min prior to
clenbuterol treatment. Control animals received a saline injection. Locomotor activity was monitored 2 h post-clenbuterol injection. Dexamethasone had no effect on the
clenbuterol-induced suppression of locomotor activity (a) and food intake (b) but blocked the clenbuterol-induced increase in hypothalamic IL-1b (c). Nadolol blocked the
clenbuterol-induced decrease in locomotor activity (d) and food intake (e) but failed to block the clenbuterol-induced increase in hypothalamic IL-1b (f). Propranolol blocked
the clenbuterol-induced decrease in locomotor activity (g) and food intake (h) and attenuated the clenbuterol-induced increase in IL-1b (i). Data expressed as means with
standard error of the mean (n = 5–6). ⁄p < 0.05, ⁄⁄p < 0.01 versus control, ++p < 0.01 versus clenbuterol control counterparts (Newman-Keuls post-hoc test).
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food consumption (Fig. 4h). Two-way ANOVA also revealed a pro-
pranolol x clenbuterol interaction for IL-1b [F(1,19) = 13.92,
p = 0.002] with propranolol suppressing the clenbuterol-induced
increase in hypothalamic IL-1b expression (Fig. 4i; p < 0.05).3.4. The selective b2-adrenoceptor agonist ICI 118,551 blocks
clenbuterol induced hypolocomotion, hypophagia and tachycardia and
clenbuterol-induced IL-1b expression in the hypothalamus
One-way ANOVA revealed an effect of treatment on IL-1bmRNA
expression in hippocampus [F(3,19) = 13.52, p < 0.0001] and
hypothalamus [F(3,19) = 29.18, p < 0.0001]. Clenbuterol increasedthe expression of IL-1b in hypothalamus and hippocampus
(Fig. 5a; p < 0.01). Pre-treatment with the b2-adrenoceptor antago-
nist ICI 118,551 attenuated the clenbuterol-induced increase in IL-
1b in both hypothalamus (p < 0.05) and hippocampus (p < 0.01).
Pre-treatment with the b1-adrenoceptor antagonist metoprolol
failed to inhibit the clenbuterol-induced increase in IL-1b. One-
way ANOVA revealed an effect of treatment on IL-1RII in hypotha-
lamus [F(3,19) = 148.53, p < 0.0001] and hippocampus [F(3,19)=35.75,
p < 0.0001], IL-1ra in hypothalamus [F(3,19) = 44.55, p < 0.0001] and
hippocampus [F(3,19) = 12.65, p < 0.0001], CD11b in hypothalamus
[F(3,19) = 14.27, p < 0.0001) and hippocampus [F(3,19) = 5.54,
p = 0.007] and GFAP in hypothalamus [F(3,19) = 10.51, p = 0.0003]
and hippocampus [F(3,19) = 12.95, p < 0.0001]. Table 2 shows that
Fig. 5. Clenbuterol-induced central IL-1b expression, hypolocomotion and tachycardia are mediated by the b2-adrenoceptor. Metoprolol (10 mg/kg), ICI 118, 551 (10 mg/kg)
or control were administered 30 min prior to administration of clenbuterol (0.5 mg/kg; i.p.) or control and rats were euthanized 4 h post-clenbuterol injection. a) Clenbuterol
increased IL-1b in hypothalamus and hippocampus and this was attenuated by pre-treatment with ICI 118,551 but not metoprolol. b) Clenbuterol suppressed locomotor
activity of rats and this effect was blocked by pre-treatment with ICI 118,551 but not metoprolol. c) Clenbuterol increased heart rate over a 24 h period. Pre-treatment with
metoprolol or ICI 118,551 attenuated the clenbuterol-induced increase in heart rate. Data expressed as means with standard error of the mean (n = 6). ⁄⁄p < 0.01 versus
control, ++p < 0.01, +p < 0.05 versus clenbuterol control counterparts (Newman-Keuls post-hoc test).
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IL-1ra and CD11b in both hypothalamus and hippocampus and
GFAP in the hippocampus. One-way ANOVA revealed an effect of
treatment on locomotor activity [F(3,20) = 68.12, p < 0.0001] and
food consumption [F(3,20) = 57.47, p < 0.0001]. Clenbuterol
decreased the time rats were active in the locomotor activity cages
(Fig. 5b; p < 0.01) compared to controls. ICI 118,551 inhibited theclenbuterol-induced decrease in active time (p < 0.01). Clenbuterol
decreased food consumption (Table 2; p < 0.01) compared to con-
trols. ICI 118,551 inhibited the clenbuterol-induced decrease in
food consumption (p < 0.01). In contrast, metoprolol had no effect
on the clenbuterol-induced increase in molecular markers,
decrease in active time or decrease in food consumption. One-
way ANOVA revealed an effect of treatment on heart rate
Table 2
Effects of the selective b2-adrenoceptor antagonist ICI 118, 551 and the selective b1-adreonceptor antagonist metoprolol on clenbuterol-induced changes in mRNA expression in
hypothalamus and hippocampus. ⁄p < 0.05; ⁄⁄p < 0.01 versus Control + Control. +p < 0.05; ++p < 0.01 versus Clenbuterol + Control.
Control + Control Clenbuterol + Control Clenbuterol + Metoprolol Clenbuterol + ICI118,551 p-value
Hypothalamus
IL-1RII 1 ± 0.16 343.78 ± 24.51⁄⁄ 329.93 ± 22.61⁄⁄ 20.37 ± 5.05++ p < 0.0001
IL-1ra 1 ± 0.02 1.91 ± 0.02⁄⁄ 1.94 ± 0.11⁄⁄ 1.57 ± 0.10⁄⁄,+ p < 0.0001
CD11b 1 ± 0.05 1.53 ± 0.10⁄⁄ 1.56 ± 0.08⁄⁄ 1.13 ± 0.07++ p < 0.0001
GFAP 1 ± 0.12 1.83 ± 0.13⁄⁄ 2.02 ± 0.15⁄⁄ 1.47 ± 0.12⁄ p < 0.0001
Hippocampus
IL-1RII 1 ± 0.18 523.58 ± 88.88⁄⁄ 498.59 ± 59.11⁄⁄ 12.79 ± 4.31++ p < 0.0001
IL-1ra 1 ± 0.24 6.12 ± 1.16⁄⁄ 5.87 ± 0.65⁄⁄ 2.39 ± 0.40++ p < 0.0001
CD11b 1 ± 0.07 1.62 ± 0.21⁄⁄ 1.41 ± 0.03⁄ 1.19 ± 0.10+ p = 0.0066
GFAP 1 ± 0.05 1.62 ± 0.14⁄⁄ 1.48 ± 0.06⁄⁄ 1.10 ± 0.09++ p = 0.0002
Locomotor Activity
Active Time(s) 651.33 ± 27 244.5 ± 23.44⁄⁄ 262.33 ± 27.28⁄⁄ 600.33 ± 15.24++ p < 0.0001
Food Consumption
Food consumed (g) 24.7 ± 0.59 9.85 ± 1.13⁄⁄ 12.87 ± 1.29⁄⁄ 23.72 ± 0.81++ p < 0.0001
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during the 12 h lights-on period [F(3,88) = 230.98, p < 0.0001]. Clen-
buterol induced tachycardia in rats, an effect which persisted for
24 h post-injection (Fig. 5c). When heart rate data were pooled
for the 12 h lights-out period clenbuterol increased heart rate
(p < 0.01) compared to controls. ICI 118,551 attenuated
clenbuterol-induced tachycardia, an effect which persisted for
24 h. When heart rate data were pooled for the 12 h lights-out per-
iod ICI 118,551 reduced clenbuterol-induced tachycardia (p < 0
.01). Notably, during the 12 h lights-on period ICI 118,551 induced
a profound reduction in clenbuterol-induced tachycardia
(p < 0.01). Metoprolol attenuated clenbuterol-induced tachycardia,
an effect which lasted approximately 5 h before wearing off. When
heart rate data were pooled for the 12 h lights-out period metopro-
lol induced a reduction in clenbuterol-induced tachycardia
(p < 0.01).3.5. Clenbuterol has a dose-dependent effect on IL-1b, IL-1ra and IL-
1RII mRNA expression and locomotor and feeding behaviour
Clenbuterol was shown to dose-dependently increase the
expression of IL-1b, IL-1RII and IL-1ra in both the hypothalamus
and hippocampus (Supplementary Table 2). The lowest dose of
clenbuterol found to induce mRNA expression of these markers
was 0.03 mg/kg. Clenbuterol also dose-dependently suppressed
locomotor activity and food consumption with 0.03 mg/kg the low-
est dose found to impact on both of these behaviours (Supplemen-
tary Table 2).3.6. Chronic low dose clenbuterol selectively activates the central IL-1
system and activates astrocytes but not microglia
Chronic clenbuterol increased IL-1b expression in hypothala-
mus and hippocampus (Fig. 6a; p < 0.001). IL-1ra expression was
induced in hippocampus (Fig. 6b; p < 0.01) but not hypothalamus.
Clenbuterol failed to induce expression of IL-1RI (Fig. 6c) but
caused a robust increase in the expression of IL-1RII in hypothala-
mus and hippocampus (Fig. 6d; p < 0.001). Importantly, clen-
buterol did not induce expression of IL-6 or IL-10 (Table 3).
Notably, clenbuterol treatment significantly reduced IL-6 expres-
sion compared to controls in the hippocampus (Table 3;
p < 0.01). Clenbuterol induced an increase in TNF-a expression in
the hypothalamus (Table 3; p < 0.05) but not the hippocampus.
Clenbuterol induced GFAP expression in hypothalamus and hip-
pocampus (Table 3; p < 0.01) and CD11b in the hypothalamus
(Table 3; p < 0.01) but not the hippocampus.3.7. Chronic low-dose clenbuterol does not induce anxiety or
depressive-like behaviour
While acute clenbuterol (0.03 mg/kg; i.p.) decreases locomotor
activity of rats (Fig. 7a; p < 0.01) chronic low-dose clenbuterol
(0.03 mg/kg; i.p.; b.i.d.) does not alter locomotor activity when
compared to controls. In the open field test (Fig. 7b) there was
no difference between control and clenbuterol-treated groups in
terms of number of visits to the inner zone (p = 0.76), time spent
in the inner zone (p = 0.38) or distance travelled in the inner zone
(p = 0.46). In the elevated plus maze test (Fig. 7c) there was no dif-
ference between control and clenbuterol-treated animals in terms
of number of entries into open arms (p = 0.96) and time spent in
the open arms (p = 0.44). Two-way ANOVA revealed no significant
clenbuterol x time interaction for saccharin preference
[F(7,42)=0.31, p = 0.95] (Fig. 7d). Chronic clenbuterol did not impact
on food intake or body-weight (Supplementary Fig. 2).4. Discussion
The results presented here confirm our previous findings
(McNamee et al., 2010a; Ryan et al., 2013) showing that systemic
administration of clenbuterol induces a selective induction of the
IL-1 system in rat brain. However, while acute treatment with
clenbuterol (0.5 mg/kg) has profound peripheral and behavioural
effects these do not represent classic sickness behaviour and can
be dissociated from induction of the IL-1 system. Instead these
effects appear to be linked to the increase in heart rate and the
induction of a mild stress-like response. In addition, chronic treat-
ment with clenbuterol, at a therapeutically relevant dose of
0.03 mg/kg, induces expression of the IL-1 system without provok-
ing anxiety or depressive-like behaviours highlighting the poten-
tial of using clenbuterol without producing adverse behavioural
effects.
A classical neuroinflammatory response and the concomitant
behavioural response associated with it are generally accepted to
be mediated by the induction and combined actions of the pro-
inflammatory and pyrogenic mediators IL-1b, TNF-a, IL-6 and
COX-II in the CNS (Beishuizen and Thijs, 2003; Blatteis et al.,
2005; Cao et al., 1995; Dantzer et al., 2008; Tizard, 2008). In study
1 we show that, as previously reported (Connor et al., 2008;
Konsman et al., 2008; O’Sullivan et al., 2009), systemically admin-
istered LPS causes a classical neuroinflammatory response indi-
cated by an increase in the expression of IL-1b, TNF-a, IL-6 and
COX-II in the rat brain and is accompanied by classical sickness
behaviour (Hart, 1988) characterized by fever, increased heart rate,
Fig. 6. Chronic low-dose clenbuterol treatment activates the IL-1 system in hypothalamus and hippocampus. Clenbuterol (0.03 mg/kg; b.i.d.) or control was administered i.p.
for 21 days. Clenbuterol induced a) IL-1b mRNA expression in hypothalamus (p < 0.001) and hippocampus (p < 0.001) and b) IL-1ra expression in hippocampus (p < 0.01)
compared to controls. Clenbuterol had no effect on c) IL-1 Type-I receptor mRNA expression hypothalamus or hippocampus. d) Clenbuterol induced expression of IL-1 Type-II
receptor in hypothalamus (p < 0.001) and hippocampus (p < 0.001) compared to controls. Data expressed as mean fold-change with standard error of the mean (n = 8).
⁄⁄p < 0.01, ⁄⁄⁄p < 0.001 versus control (Student’s t-test).
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trast, clenbuterol selectively increases expression of the central
IL-1 system in the absence of a classical inflammatory and beha-
vioural response. Notably, the clenbuterol-induced increase in
the IL-1 system is more robust than that associated with LPS. Sinceprevious studies have shown that acute administration of clen-
buterol has no effect on the expression of the IL-1 Type I receptor
or IL-1 accessory protein in rat CNS, both of which are imperative
for IL-1 signalling (McNamee et al., 2010a), the expression of iNOS
was evaluated as a down-stream measure of IL-1 signalling and we
Table 3
Effects of chronic clenbuterol on mRNA expression in hypothalamus and hippocam-
pus. ⁄p < 0.05; ⁄⁄p < 0.01 versus Control (Student’s t-test).
Control Chronic clenbuterol p-value
Hypothalamus
TNF-a 1 ± 0.07 1.23 ± 0.07⁄ p = 0.0406
IL-6 1 ± 0.02 0.93 ± 0.15 p = 0.2162
IL-10 1 ± 0.14 0.88 ± 0.10 p = 0.4928
CD11b 1 ± 0.05 1.23 ± 0.05⁄⁄ p = 0.0078
GFAP 1 ± 0.09 1.58 ± 0.15⁄⁄ p = 0.0050
Hippocampus
TNF-a 1 ± 0.10 1.26 ± 0.09 p = 0.0722
IL-6 1 ± 0.08 0.68 ± 0.08⁄⁄ p = 0.0052
IL-10 1 ± 0.19 1.48 ± 0.34 p = 0.3164
CD11b 1 ± 0.09 1.20 ± 0.09 p = 0.1261
GFAP 1 ± 0.07 1.37 ± 0.06⁄⁄ p = 0.0018
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comparison to LPS. Thus, it appears that, in line with a previous
report (Shirato et al., 2007), clenbuterol induces a mild stress
response as opposed to sickness behaviour. This we suggest is
caused by its profound peripheral effects observed in study 2, in
particular its effects on heart rate. Clenbuterol has previously been
reported to induce changes in heart rate in both in vitro and in vivo
systems (Hoey et al., 1995; Mazzanti et al., 2007). While the b1-
adrenoceptor is the pre-dominant adrenoreceptor subtype
expressed in the heart (Brodde et al., 2006; Wallukat, 2002) and
although clenbuterol acts principally on b2-adrenoceptors, the
clenbuterol-induced increase in heart rate is suggested to be medi-
ated by an interplay between both b1- and b2-adrenoceptor sub-
types (Mazzanti et al., 2007). In line with this, the clenbuterol-
induced effect on heart rate in this study was found in study 4 to
be significantly attenuated by the selective b2-adrenoceptor antag-
onist ICI 118,551 but also to a lesser extent by the selective b1-
adrenoceptor antagonist metoprolol. The dose of metoprolol
(10 mg/kg) used here was double the dose of 5 mg/kg which was
shown previously by Zhang et al. (2010) to attenuate the
clenbuterol-induced increase in heart rate.
As mentioned, clenbuterol induces a profound but selective
increase in the expression of the central IL-1 systemwhich has pre-
viously been implicated as a key mediator of neuroinflammation
(Allan et al., 2005; Griffin et al., 2006). However, there is now a
general consensus that inflammatory mediators including IL-1b
can exert both adaptive and maladaptive responses in the brain,
depending on the concentration, the duration of exposure and
overall immune status (Goshen et al., 2007; Pinteaux et al., 2006;
Spulber et al., 2009). While there is a body of research outlining
the contribution of IL-1b to the neurodegenerative process (Allan
et al., 2005), evidence also indicates that IL-1bmay elicit neuropro-
tective effects both in vitro and in vivo (Mason et al., 2001; Shaftel
et al., 2007; Tanabe et al., 2009; Tomozawa et al., 1995). Taken
together, these findings suggest that IL-1b can have either protec-
tive or detrimental effects in the CNS depending on the context,
and that constitutive expression of IL-1b is necessary for many
aspects of normal brain function. The clenbuterol-induced increase
in IL-1b occurs in tandem with an increase in IL-1ra and IL-1RII
which, as previously described (Arend, 2002; Bessis et al., 2000;
Colotta et al., 1994), may act to prevent excessive or prolonged
activation of the IL-1 system. Moreover, we have previously
reported that the clenbuterol-induced increase in IL-1b is accom-
panied by increased activation of the mitogen-activated protein k
inase/extracellular-signal-regulated kinase (MAP kinase/ERK) sig-
nalling pathway which is associated with pro-survival effects in
neurons but fails to activate c-Jun N-terminal kinase (JNK) and
P38 MAP kinase pathways, which have been implicated in mediat-
ing the detrimental effects of IL-1 in the brain (McNamee et al.,2010a). The results presented in study 4 show that the
clenbuterol-induced increase in IL-1b, and also IL-1ra and the IL-
1 Type II receptor, expression is mediated by b2-adrenoceptors as
expression could be blocked by ICI 118,551 but not metoprolol.
It has been demonstrated that astrocytes support hippocampal-
dependent memory and long-term potentiation via IL-1 signalling
(Ben Menachem-Zidon et al., 2011). Thus, in order to get an indica-
tion of the cellular source of clenbuterol-induced IL-1b we exam-
ined expression of the astrocytic marker (GFAP) and microglial
activation marker (CD11b) and found an increase in GFAP expres-
sion in both hypothalamus and hippocampus. Further work is
required to clarify the cellular source of clenbuterol-induced IL-
1b. In line with previous in vitro work (Junker et al., 2002), the
increase in GFAP, observed following systemic clenbuterol admin-
istration is mediated by b2-adrenoceptors since in study 4 ICI
118,551 impeded the expression of GFAP in hippocampus and
hypothalamus.
Previous reports have shown that peripheral injection of IL-1b
results in prolonged increases in brain noradrenaline, an effect
demonstrated to reduce the locomotor activity of rats
(Wieczorek and Dunn, 2006). We show here that clenbuterol
has a more profound impact on locomotor activity than LPS, an
effect which may be linked to the sizeable increase in central
IL-1b. However, previous studies have shown that the
clenbuterol-induced reduction in locomotor activity can be atten-
uated by administration of hydrophilic non-selective b-
adrenoceptor antagonists which are incapable of penetrating the
blood brain barrier indicating that the effects of clenbuterol on
locomotor activity may be mediated by peripheral and not cen-
tral mechanisms (Geyer and Frampton, 1988; O’Donnell, 1993).
Therefore, we sought to determine if the suppression of locomo-
tor activity induced by clenbuterol was dependent on its ability
to induce central IL-1b expression. We have previously demon-
strated that pre-treatment with 1 mg/kg of the synthetic gluco-
corticoid dexamethasone can inhibit clenbuterol-induced central
IL-1b expression without altering its ability to induce the anti-
inflammatory mediators IL-1ra and IL-1RII suggesting a mecha-
nistic dissociation between the ability of b2-adrenoceptor activa-
tion to induce IL-1b and its negative regulators (Ryan et al.,
2011). Thus, in study 3 we pre-treated rats with dexamethasone
to ascertain a role for central IL-1b in the clenbuterol-induced
suppression of locomotor activity and food consumption. How-
ever, while dexamethasone blocked the clenbuterol-induced
increase in central IL-1b it failed to inhibit its suppressive effect
on locomotor activity and food consumption. Moreover, the
peripherally acting b-adrenoceptor antagonist nadolol failed to
inhibit clenbuterol-induced central IL-1b expression but com-
pletely blocked the suppressive effect on locomotor activity and
food consumption. Notably, treatment with propranolol, a brain
penetrable non-selective b-adrenoceptor antagonist, blocked both
the induction of central IL-1b and suppression of locomotor activ-
ity and food consumption. Taken together these data suggest that
peripheral b-adrenoceptors mediate the suppression of locomotor
activity and food consumption induced by clenbuterol and that
this occurs independently of its ability to induce central IL-1b
expression. However, this is not surprising as previous studies
indicate that peripheral b-adrenoceptors mediate the suppressive
effect of clenbuterol on behaviour (Geyer and Frampton, 1988;
O’Donnell, 1993). Moreover, we suggest that the clenbuterol-
induced behavioural effects are mediated by the impact of clen-
buterol on cardiac b2-adrenoceptors and the increase in heart rate
since the effects were completely blocked when rats were pre-
treated with ICI 118,551 but not metoprolol. This same study
showed that clenbuterol reduced food intake and this effect
was reversed when the clenbuterol-induced tachycardia was
attenuated by ICI 118,551. Thus while exogenous IL-1b is known
Fig. 7. Chronic low-dose clenbuterol does not induce anxiety or depressive-like behaviours. Clenbuterol (0.03 mg/kg; b.i.d.) or control were administered i.p. for 21 days. a)
Acute clenbuterol significantly reduced locomotor activity (p < 0.001) compared to control counterparts but chronic clenbuterol did not impact on locomotor activity. Chronic
clenbuterol did not alter behaviour in b) the open field test with respect to number of visits to the inner zone, time spent in the inner zone, distance travelled in the inner zone
as assessed by Student’s t-test. Chronic clenbuterol did not alter behaviour in c) the elevated plus maze with respect to number of entries into open arms or time spent in open
arms as assessed by Student’s t-test. d) Chronic clenbuterol did not alter saccharin preference over the 21 day experimental period as assessed by a two-way repeated-
measures ANOVA. Data expressed as means with standard error of the mean (a–c: n = 8; d: n = 4). ⁄⁄⁄p < 0.001 versus control (Student’s t-test).
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tor activity and feeding (Bluthe et al., 1996; Kent et al., 1992,
1994; Plata-Salaman et al., 1988; Swiergiel and Dunn, 2000,
2007), the results of the present study clearly show that the
induction of central IL-1b by clenbuterol does not play a role in
the behavioural effects elicited by this drug.Study 5 identified that the lowest dose of clenbuterol capable of
impacting on immune processes in the CNS was 0.03 mg/kg, there-
fore this dose was chosen to be used for chronic treatment in study
6 to determine if its central and peripheral effects persist over
time. Notably, this dose is in line with that already used therapeu-
tically in humans (Daubert et al., 2007). A dose of 10–20 lg
K.M. Ryan et al. / Brain, Behavior, and Immunity 56 (2016) 114–129 127(0.01–0.02 mg) is efficaciously used in humans for bronchodilation
over prolonged periods up to twice or three times daily (Hida et al.,
1985; Kamburoff et al., 1977; Wheatley, 1982). While we show
that this low-dose of clenbuterol increases heart rate following
acute administration, its effects are transient and persist for
approximately 10 h before returning to baseline (Supplementary
Fig. 1). This is noteworthy since clenbuterol toxicity in humans is
known to lead to symptoms including headache, dizziness, ner-
vousness, peripheral vasodilation, hypothermia and tachycardia,
however, previous reports indicate that clenbuterol causes an
increase in blood flow and heart rate during the initial days of
treatment but these effects are found to subside with continued
treatment (Hoey et al., 1995). We show that chronic treatment
with low-dose clenbuterol induces a 2.5–3 fold increase in IL-1b
mRNA expression compared to a 15–40 fold increase observed fol-
lowing acute administration of the same dose. Thus, IL-1b expres-
sion subsides following continued clenbuterol administration in
hypothalamus and hippocampus. As before, we found that chronic
clenbuterol increased expression of the anti-inflammatory mole-
cules IL-1ra and IL-1RII.
Considering the evidence that exogenous IL-1b can precipitate
symptoms of depression and anxiety we sought to investigate
the effect of chronic treatment with clenbuterol on anxiety and
depression-like behaviours (anhedonia) in rats and show that
chronic clenbuterol does not induce either depression- or
anxiety-like behaviours. In addition, chronic clenbuterol had no
effect on body weight or food intake which suggests that the
reduction in feeding seen after acute clenbuterol administration
is transient and the animals regain their appetite and maintain a
healthy weight with continued treatment. There is now a general
consensus that inflammatory mediators including IL-1b can exert
both adaptive and maladaptive responses in the brain, depending
on the concentration, the duration of exposure and the overall
immune environment (Goshen et al., 2007; Pinteaux et al., 2006;
Spulber et al., 2009). The fact that clenbuterol-induced IL-1b does
not induce an anxious or depressed phenotype following a pro-
longed period of treatment could be partly due to the low concen-
tration of IL-1b expressed or to the induction of IL-1ra and the IL-
1RII.
It is well documented that stimulation of b-adrenoceptors
either directly or through increased release of noradrenaline in
response to various stressors can induce expression of pro-
inflammatory cytokine, in particular IL-1b, both peripherally and
centrally (Blandino et al., 2006, 2009; Johnson et al., 2005, 2004).
Moreover, blocking noradrenaline reuptake facilitates increases
in IL-1b both peripherally and centrally under both basal and
stress-induced conditions (Blandino et al., 2006). Stress has also
been found to increase the expression of IL-1RII in the brain in tan-
dem with IL-1b (Hueston and Deak, 2014), however, in contrast to
our findings no change was found in IL-1ra expression showing
that the effects of stress may be selective for IL-1b and its soluble
decoy receptor. In such studies microglia appear to be the major
producer of IL-1b as stress-induced central increases in IL-1b can
be blocked by pre-treatment with the microglial inhibitor minocy-
cline (Blandino et al., 2006, 2009) while such stressors decrease
astrocytic activation as indicated by a reduction in GFAP expres-
sion (Blandino et al., 2009). Such findings are in contrast to the
results we have presented both here and previously in relation to
stimulation of b2-adrenoceptors with clenbuterol which activates
astrocytes and has other anti-inflammatory and neuroprotective
actions (Gleeson et al., 2010; McNamee et al., 2010b; Ryan et al.,
2013). Moreover, in a study by Hueston and Deak (2014) treatment
with dexamethasone had no effect on the stress-induced increase
in central IL-1bwhich is in direct contrast to our results here which
showed that clenbuterol-induced IL-1b was blocked by dexam-
ethasone suggesting different mechanisms are at play. However,it is worth noting that previous studies have shown that stress-
induced increases in central IL-1b can sensitize the central IL-1 sys-
tem and the hypothalamic-pituitary-adrenal-axis to subsequent
immune challenge resulting in a more exaggerated central
response (Johnson et al., 2004). Thus, further studies are necessary
to explore the possibility that clenbuterol-induced IL-1b could
have a priming effect on the CNS in response to a neuroinflamma-
tory stimulus.
Overall the peripheral effects of clenbuterol (0.5 mg/kg) can be
dissociated from its central effects and the increased expression of
the anti-inflammatory molecules IL-1ra and IL-1RII may serve to
limit the effects of clenbuterol-induced IL-1b on brain function
and behaviour. Data following repeated administration of a low
dose of clenbuterol (0.03 mg/kg) suggests that it or other selective
b2-adrenoceptor agonists could have the potential to combat the
neurodegenerative process without inducing unwanted symptoms
of depression and anxiety. However, while both clenbuterol and
noradrenaline reuptake inhibitors have neuroprotective (Culmsee
et al., 1999a; Gleeson et al., 2010; Zhu et al., 1999) and memory
enhancing properties (Clinton et al., 2006; Ramos et al., 2008;
Seu et al., 2009), any role that IL-1 system components may have
in such neuroprotective or memory enhancing actions of these
drugs remains to be determined.Conflict of Interest
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